ラマト・ガンで最高の診断科医師 - トップ3名の医師

Department:

Gastrointestinal Cancer Department

Specialties:

Internal Medicine, Medical Oncology, Cancer Epidemiology

Prof. Ben Boursi is a leading specialist in Internal Medicine, Medical Oncology, and Radiotherapy at Sheba Medical Center. He earned his medical degree with distinction (cum laude) from the School of Medicine at Tel Aviv University.

He completed his residency in Internal Medicine at Sourasky Medical Center in Tel Aviv, followed by advanced subspecialty training in Gastrointestinal Oncology and Cancer Epidemiology at the University of Pennsylvania, USA.

Academic and Research Appointments

Prof. Boursi holds an academic position within the Department of Epidemiology and Preventive Medicine at the School of Medicine, Tel Aviv University. In addition, he serves as an Associate Scholar at the Perelman School of Medicine, University of Pennsylvania.

Research and Scientific Contributions

Prof. Boursi’s research is centered on developing innovative therapeutic approaches in oncology, with a particular focus on the role of the microbiome in cancer development and treatment response.

He is internationally recognized as a leader in microbial modulation in cancer therapy and founded the ECOG-ACRIN Microbiome Working Group. His work has been published in leading scientific journals, including Science, and presented at major global oncology conferences, as well as featured in ASCO educational platforms and podcasts.

Alongside his research, Prof. Boursi is actively involved in academic teaching, delivering lectures on host–microbiome interactions at Tel Aviv University and Bar-Ilan University.

His research also extends to cancer prevention and early detection. He has developed predictive models for early diagnosis of colorectal and pancreatic cancers, which are currently undergoing clinical evaluation.

Clinical Expertise

Gastrointestinal oncology

Current Position

Physician, Gastrointestinal Cancer Department

Education and Training

B.Med.Sc (Summa cum laude), School of Medicine, Tel Aviv University

MD (Magna cum laude), School of Medicine, Tel Aviv University

Clinical and Research Fellowship in Gastrointestinal Oncology and Cancer Epidemiology, Perelman School of Medicine, University of Pennsylvania

Elective Training in Medical Oncology, MD Anderson Cancer Center

Elective Training in Medical Oncology, Mayo Clinic

Advanced Research Training, Weizmann Institute of Science

Board Certifications

Internal Medicine

Medical Oncology

Professional Memberships

Israeli Association of Clinical Oncology and Radiotherapy (ISCORT)

American Society for Cancer Research

Selected Publications

Immune-related adverse events as predictors of durable response to BRAF inhibitors in metastatic melanoma with BRAF V600 mutation

Ben-Betzalel G, Baruch EN, Boursi B, et al.

Re-evaluating the IDEA classification: Novel predictive and prognostic markers in stage III colon cancer

Margalit O, Mamtani R, Yang YX, Boursi B, et al.

Prognostic significance of carcinoembryonic antigen (CEA) levels in stage I–II colon cancer

Margalit O, Mamtani R, Yang YX, Boursi B, et al

Professional Profile

Dr. Almog Ben-Yaacov is a highly experienced surgeon specializing in general and oncological surgery. He graduated with honors from Semmelweis University Medical School in 2006. Following graduation, he completed two years of training in cardiac surgery, after which he continued with six additional years of advanced training in general surgery.

He currently serves as a senior surgeon at Sheba Medical Center. His clinical focus includes cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC), as well as the management of gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, Dr. Ben-Yaacov has performed over 200 HIPEC procedures.

Advanced Training

Dr. Ben-Yaacov has completed multiple specialized international training programs, including:

ESSO-certified HIPEC surgery course in Hamburg, Germany

Microwave liver ablation training in Reims, France

NanoKnife (irreversible electroporation) training at King’s College, London

In 2019, he further expanded his expertise through advanced surgical oncology training at Memorial Sloan Kettering Cancer Center, New York, USA.

Clinical Expertise & Procedures

Cytoreductive surgery with HIPEC

Resection of abdominal wall metastases

Minimally invasive and laparoscopic surgery

General and gastrointestinal surgery

Colorectal surgery

Laparoscopic cholecystectomy

Abdominal surgery

Surgical oncology

NanoKnife (irreversible electroporation)

Laparotomy

Current Position

Attending Surgeon, Department of General and Oncological Surgery (Surgery C)

Education & Surgical Training

MD (with honors), Semmelweis University Medical School, Hungary

Cardiothoracic Surgery Training, Sheba Medical Center

General Surgery Training, Montefiore Medical Center (Einstein Campus), New York, USA

General Surgery Training, Rabin Medical Center (Beilinson Campus), Israel

Board Certifications

General Surgery

Surgical Oncology

Selected Publications

Correlation Between Intraoperative and Pathological Findings in Patients Undergoing CRS and HIPEC

Berger Y, Jacoby H, Kaufmann MI, Ben-Yaacov A, et al.

Laparoscopic vs Open Hartmann’s Reversal: A Decade-Long Multicenter Retrospective Study

Horesh N, Lessing Y, Rudnicki Y, Ben-Yaacov A, et al.

Readmission Rates and Risk Factors Following CRS and HIPEC for Peritoneal Surface Malignancies

Dreznik Y, Hoffman A, Hamburger T, Ben-Yaacov A, et al.

Department:

The Endocrinology and Diabetes Research Center

The Endocrine Institute & Endocrine Oncology Bioinformatics Lab

Specialties:

Neuroendocrine Tumors

Professional Profile

Prof. Amit Tirosh is a senior endocrinologist with extensive expertise in the management of neuroendocrine tumors (NETs). He serves as the Head of the Neuroendocrine Tumors Service at the Institute of Endocrinology, Sheba Medical Center.

His clinical and academic focus includes hereditary syndromes associated with neuroendocrine tumor development. Prof. Tirosh is affiliated with the National Institutes of Health (NIH) in the field of MEN1 syndrome. He is also part of an international expert panel on von Hippel–Lindau (VHL) disease and has contributed to clinical guidelines for the management of VHL patients. At Sheba Medical Center, he acts as the primary contact physician within the multidisciplinary VHL clinic.

Research and Academic Activity

Prof. Tirosh leads an active research program focused on bioinformatics in endocrine oncology, with particular emphasis on neuroendocrine tumors. As Head of the Endocrine Oncology Bioinformatics Laboratory, he collaborates with leading research institutions in the United States, Italy, and Germany, as well as with scientists from the Weizmann Institute of Science.

In his role at the Endocrinology and Diabetes Research Center, he provides patients with advanced, state-of-the-art treatment options for NETs. He is also actively involved in teaching and regularly lectures medical students at Tel Aviv University’s Faculty of Medicine.

Clinical Expertise

Endocrinology

Neuroendocrine tumors (NETs)

Peptide Receptor Radionuclide Therapy (PRRT)

Current Position

Head of Neuroendocrine Tumors Service,

The Endocrine Institute & Endocrine Oncology Bioinformatics Lab,

The Endocrinology and Diabetes Research Center

Education and Training

MD, Hadassah Medical School, Hebrew University of Jerusalem

Residency in Internal Medicine, Assaf HaRofeh Medical Center

Fellowship in Endocrinology, Rabin Medical Center

Advanced training in Neuroendocrine Tumors and Endocrine Tumor Genetics, National Institutes of Health (Maryland, USA)

Board Certification

Endocrinology

Professional Memberships

Israeli Society of Endocrinology

American Endocrine Society

European Neuroendocrine Tumors Society

Scientific Publications

Prof. Tirosh is the author of more than 40 peer-reviewed publications in leading medical journals, including JAMA, Oncology, Gastroenterology, Cancer, Journal of Clinical Endocrinology & Metabolism, and Radiology.

Selected articles include:

Postoperative hyperglycemia following insulinoma resection: incidence and management

Nockel P, Tirosh A, et al.

Radiation exposure from CT surveillance in patients with VHL-associated pancreatic tumors

Tirosh A, Journy N, et al.

Radioguided surgery using Gallium-68 DOTATATE in neuroendocrine tumors

El Lakis M, Tirosh A, et al.